Prevalence of Lipohypertrophy and Associated Risk Factors in Insulin-Treated Patients With Type 2 Diabetes Mellitus

CITEDBY Reports

  1. S. J. Jacober, M. J. Prince, J. M. Beals, M. L. Hartman, Y. Qu, H. Linnebjerg, P. Garhyan, A. Haupt, . Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action. Diabetes, Obesity and Metabolism, 2016; 18(): 3.
    Crossref
  2. Sandro Gentile, Felice Strollo, Antonio Ceriello, . Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?. Diabetes Therapy, 2016; 7(3): 401.
    Crossref
  3. Sandro Gentile, Felice Strollo, Antonio Ceriello, . Lipodistrophy and Associated Risk Factors in Insulin-Treated People With Diabetes. International Journal of Endocrinology and Metabolism, 2016; In Press(In Press): .
    Crossref
  4. Edurne Zabaleta-del-Olmo, Bogdan Vlacho, Lina Jodar-Fernández, Ana-María Urpí-Fernández, Iris Lumillo-Gutiérrez, Josep Agudo-Ugena, Rosa Morros-Pedrós, Concepción Violán, . Safety of the reuse of needles for subcutaneous insulin injection: A systematic review and meta-analysis. International Journal of Nursing Studies, 2016; 60(): 121.
    Crossref
  5. Ayman A. Al Hayek, Asirvatham A. Robert, Rim B. Braham, Mohamed A. Al Dawish, . Frequency of Lipohypertrophy and Associated Risk Factors in Young Patients with Type 1 Diabetes: A Cross-Sectional Study. Diabetes Therapy, 2016; 7(2): 259.
    Crossref